Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 11/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL17746100 | 0.79 | TDP1 (0.41) | SIRT3TDP1MAPTALDH1A1TP53 | |
| SCHEMBL2770960 | 0.79 | SIRT3 (0.61) | SIRT3TDP1MAPTALDH1A1TP53 | |
| SCHEMBL5014069 | 0.79 | KDM4C (0.49) | SIRT3TDP1MAPTALDH1A1TP53 | |
| SCHEMBL27713021 | 0.77 | TDP1 (0.42) | SIRT3TDP1MAPTALDH1A1TP53 | |
| SCHEMBL17746099 | 0.77 | KDM4C (0.47) | SIRT3TDP1MAPTALDH1A1TP53 | |
| SCHEMBL31146203 | 0.74 | KDM4E (0.47) | SIRT3TDP1MAPTALDH1A1GAA | |
| SCHEMBL7393208 | 0.73 | TDP1 (0.39) | SIRT3TDP1MAPTALDH1A1TP53 | |
| SCHEMBL28499412 | 0.73 | TDP1 (0.39) | SIRT3TDP1MAPTALDH1A1TP53 | |
| SCHEMBL7899172 | 0.71 | ERN1 (0.38) | SIRT3TDP1MAPTALDH1A1GSK3B | |
| SCHEMBL28590209 | 0.69 | LATS1 (0.38) | TDP1MAPTTSHRGPBAR1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041124-B1 | PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS | MSD OSS BV (NL) | 2013-06-26 | — | — | EP | disclosed |
| EP-2041124-B1 | PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS | MSD OSS BV (NL) | 2013-06-26 | — | — | EP | disclosed |
| US-7820707-B2 | Heterocyclic derivatives | N.V. ORGANON (NL) | 2010-10-26 | — | — | US | disclosed |
| US-7820707-B2 | Heterocyclic derivatives | N.V. ORGANON (NL) | 2010-10-26 | — | — | US | disclosed |
| US-7820707-B2 | Heterocyclic derivatives | N.V. ORGANON (NL) | 2010-10-26 | — | — | US | disclosed |
| EP-2041124-A1 | PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS | N.V. Organon (NL) | 2009-04-01 | — | — | EP | disclosed |
| US-20080255086-A1 | Heterocyclic Derivatives | N.V. ORGANON (NL) | 2008-10-16 | — | — | US | disclosed |
| US-20080255086-A1 | Heterocyclic Derivatives | N.V. ORGANON (NL) | 2008-10-16 | — | — | US | disclosed |
| US-20080255086-A1 | Heterocyclic Derivatives | N.V. ORGANON (NL) | 2008-10-16 | — | — | US | disclosed |
| WO-2008003452-A1 | PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS | N.V. ORGANON (NL) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008003452-A1 | PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS | N.V. ORGANON (NL) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255086-A1 | Heterocyclic Derivatives | GRIN2C, GRIN3A, GRIN1 | SIRT3 1119/4885TDP1 2041/4885MAPT 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.